Clinical trials
Glioblastoma - Category clinical trials
Below are recruiting glioblastoma - category clinical trials, each written for real people, not researchers. We’re tracking 355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05775458Recruiting
Study of treatments for aggressive brain tumor cell damage
This study looks at glioblastoma (GBM), a very aggressive brain tumor, and how “brain cell overload” (glutamate excitotoxicity) may affect tumor growth. It focuses on adults who are planned for complete tumor removal, followed by standard radiation and chemotherapy.
Milan, MilanAges 18 years+ - NCT06954636Recruiting
Smell test to predict glioblastoma outcomes (newly diagnosed)
This study looks at whether a simple smell test can help predict how glioblastoma will progress. It is for people who are newly diagnosed and have not started treatment yet.
EssenAges 18 years+ - NCT06183983Recruiting
Advanced MRI for better glioblastoma radiation
This trial tests whether using advanced MRI scans before radiation therapy can help doctors target the tumor more precisely and possibly improve outcomes for people with glioblastoma. It aims to make radiation treatment more personalized.
Rotterdam, South HollandAges 18 years+ - NCT06934889RecruitingPhase 1
Study of investigational drugs with ERAS-801 for glioblastoma
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT06930846Recruiting
Brain cancer cognitive training study
This study tests a home-based program called HOBSCOTCH-CA to help with memory and thinking problems after brain cancer treatment. The program uses phone and internet sessions to teach self-management skills.
Lebanon, New HampshireAges 18 years+ - NCT06926075RecruitingPhase 1/Phase 2
Early trial of KESONOTIDE™ for solid tumors
This trial tests a new tablet called KESONOTIDE™ for people with solid tumors that have spread. The goal is to see if it can help when other treatments have stopped working or are not an option.
Kogarah, New South WalesAges 18 years+ - NCT06910306Recruiting
DaRT alpha radiation for recurrent glioblastoma
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
Scottsdale, ArizonaAges 18–85 - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
Birmingham, AlabamaAges 18 years+ - NCT04765098RecruitingPhase 2
Tamoxifen or Etoposide for recurring brain tumor after prior treatment
This trial tests whether tamoxifen works as well as etoposide in people whose glioblastoma has come back after standard chemotherapy and radiation with temozolomide. It aims to find a better medication option for controlling the tumor after the first return.
Edmonton, AlbertaAges 18–65 - NCT05785754RecruitingPhase 1
Early drug study for advanced solid tumors
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
Birmingham, AlabamaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06894225RecruitingPhase 2
Targeted drug for recurrent brain cancer with STAT3 marker
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
SingaporeAges 21 years+ - NCT06883747RecruitingEarly Phase 1
Study of BMS-986504 for recurrent brain tumor
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06888817RecruitingPhase 3
Bevacizumab vs steroids for brain radiation injury
This trial tests if bevacizumab works better than steroids for people with brain swelling caused by radiation. If you have this condition and meet certain health requirements, you may join.
AmsterdamAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT06850766Recruiting
Timing of chemotherapy (morning vs evening) for glioblastoma
This trial tests whether taking the chemotherapy drug temozolomide in the morning or in the evening works better and causes fewer side effects for people with a type of brain cancer called glioblastoma.
London, OntarioAges 18 years+ - NCT04266977Recruiting
Low-dose steroid timing for newly diagnosed brain tumor surgery
This trial looks at using dexamethasone (a steroid medicine) in a more restricted way for people newly diagnosed with likely glioblastoma who are planned for brain surgery. The goal is to see whether limiting steroid use can still control symptoms while reducing steroid exposure.
Sankt Gallen, St.GallenAges 18–90 - NCT06773481RecruitingPhase 1
BC008-1A injection for recurrent grade 4 glioma
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06831526RecruitingEarly Phase 1
Chemoradiation with or without azeliragon for new glioblastoma
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
St Louis, MissouriAges 18 years+ - NCT06835803RecruitingPhase 2
Intensified radiation for older adults with glioblastoma
This trial tests whether a more focused, stronger dose of radiation can improve outcomes for people 65 and older with newly diagnosed glioblastoma. It compares this approach to standard radiation to see if it's safe and effective.
Boston, MassachusettsAges 65 years+ - NCT06815432RecruitingPhase 1
GPC-3 CAR T cells for recurrent GPC-3 positive glioblastoma
This trial tests whether a special type of immune cell (called CAR T cells) can fight a brain tumor called glioblastoma that has come back. The cells are made to target a protein on the tumor cells, and the study will see if this treatment is safe and helpful.
Houston, TexasAges 21–70 - NCT06816927RecruitingPhase 2
Immunotherapy trial for glioblastoma with nivolumab and relatlimab
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
New York, New YorkAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+
Hear when a new Glioblastoma - Category trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioblastoma - category?
- Yes. Clin2 currently lists 355 recruiting glioblastoma - category studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioblastoma - category trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioblastoma - category trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.